By Jacqueline Renfrow
Cancer does not take a break during a pandemic. Here's a patient experience about what it was like returning for treatment amid fears of contracting the virus.
read more
By Ben Adams
AbbVie and Harvard have signed up to a new $30 million early-stage infectious disease pact with coronavirus and hemorrhagic fever viruses two key targets of the deal.
read more
By Fraiser Kansteiner
A University of Texas research team had already developed its thin-film freezing technology when COVID-19 struck. With the drug delivery platform primed to create dry powder formulations of established meds, the team set to work creating an inhaled version of the antiparasitic niclosamide for coronavirus testing—and then targeted Gilead Sciences' remdesivir.
read more
By Paige Minemyer
As many Americans drop out of employer plans and seek coverage elsewhere amid the pandemic, insurers will need to adjust their marketing strategies to reach them more effectively, a new report shows.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
Moderna could supply at least 40 million shots to Japan. J&J will launch a phase 2 vaccine study in Europe next week. Laurent Pharma got the OK to run a phase 2 on its COVID-19 drug. Sinovac snared emergency approval for its shot in China; plus, Jacobson will help Fosun crank out BioNTech shots in Hong Kong.
read more
By Kyle Blankenship
Drugmakers on the hunt for a COVID-19 vaccine have promised massive supply rollouts in the coming months if their candidates pass regulators' scrutiny. But promises and results are very different things: For two highly touted mRNA-based shots, cold-storage requirements could hobble their launches.
read more
By Danielle Renwick, The Guardian,Shoshana Dubnow, Kaiser Health News
The Guardian and KHN release new figures showing that, among health care workers, a disproportionate number of immigrants and minorities have died.
read more
By Heather Landi
Remote monitoring startup Stasis Labs is rapidly scaling its operation to meet demand in the U.S. created by the pandemic. The company built a cloud-based remote monitoring system that's easy to install and it's providing to be essential for outpatient centers. Here's why Stasis Labs believes remote care is going to be the future of healthcare delivery.
read more
By Fraiser Kansteiner
Romark's manufacturing site in Manati, Puerto Rico, snagged a thumbs up from the FDA to to produce the diarrhea drug Alinia for the U.S. market. The approval is expected to tee up 300 new hires over the next three years; plus, Romark will use the facility to supply trials of its COVID hopeful, NT-300.
read more
